Klacid

Clarithromycin, the active ingredient in Klacid, is a macrolide antibiotic presented as an oral tablet for systemic use. It treats a range of bacterial infections, including respiratory, sinus, skin and soft‑tissue infections, and is used in combination regimens for Helicobacter pylori eradication in adults and children as prescribed by a healthcare professional.

GNH USA supplies Klacid as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable sourcing for global healthcare providers.

Klacid (clarithromycin) is indicated for several bacterial infections affecting the respiratory, sinus, skin and gastrointestinal systems.

Community‑acquired pneumonia: eliminates the causative bacteria and improves recovery. Acute bacterial sinusitis: reduces sinus inflammation and bacterial load. Skin and soft‑tissue infections: treats cellulitis, erysipelas and other bacterial skin conditions. Helicobacter pylori eradication (in combination therapy): contributes to successful eradication regimens for ulcer disease.

Clarithromycin is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Diarrhea: frequent loose stools. - Abdominal pain: cramping or discomfort. - Altered taste: metallic or bitter sensation. - Headache: transient mild headache. - Vomiting: occasional episodes.

Serious or Rare Side Effects: - Clostridioides difficile‑associated diarrhea: severe colitis. - QT interval prolongation: risk of cardiac arrhythmia. - Severe allergic reactions: anaphylaxis, rash, or angioedema. - Hepatic dysfunction: elevated liver enzymes or hepatitis. - Neutropenia: reduced white blood cell count. - Stevens‑Johnson syndrome: severe skin and mucous membrane reaction.

Before initiating therapy, consider the following safety measures.

Assess renal and hepatic function: adjust use if impairment is present. Monitor cardiac status: avoid in patients with known QT prolongation. Avoid in known hypersensitivity: discontinue if allergic reaction occurs. Use caution during pregnancy: category unknown, weigh benefits against risks. Review concomitant medications: potential for drug‑drug interactions. Store at ambient temperature: keep in the original pack, protect from moisture.

Clarithromycin interacts with several medicines; awareness of the interaction level guides management.

Major Interactions (Avoid): - Cisapride: risk of serious cardiac arrhythmias. - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may cause toxic levels of clarithromycin. - Ergot alkaloids: increased risk of ergotism. - Statins metabolized by CYP3A4 (e.g., simvastatin): heightened risk of myopathy. - Colchicine in renal impairment: risk of colchicine toxicity.

Moderate Interactions (Monitor Closely): - Warfarin: may enhance anticoagulant effect, monitor INR. - Carbamazepine: may reduce clarithromycin levels. - Phenytoin: may lower clarithromycin concentrations. - Oral contraceptives: possible reduction in efficacy, advise backup method. - Digoxin: may increase serum digoxin levels, monitor for toxicity.